BARCELONA—There was no improvement in biochemical progression free survival among patients who had their high-risk localized prostate cancers treated with elective pelvic nodal irradiation compared with those who had prostate radiation only. That...
BARCELONA – For patients with locally advanced cervical cancer, combining intracavitary and interstitial (IC/IS) brachytherapy techniques should be the benchmark treatment. That’s according to results from the retroEMBRACE study that...
BARCELONA – The 3rd European Society for Radiotherapy & Oncology Forum — ESTRO — was held this year in Barcelona featuring all aspects of the radiation oncology field. Oncology Times reporter Sarah Maxwell spoke to ESTRO president Philips...
BARCELONA—Men with intermediate- or high-risk prostate cancer who were treated with low dose rate prostate brachytherapy (LDR-PB) were twice as often cancer-free at five years compared to those given dose-escalated external beam radiation therapy...
BARCELONA – Brachytherapy with or without external beam radiation improved survival in patients with early-stage, inoperable endometrial cancer. That’s according to findings of a population-based analysis that looked at data from the...
GENEVA— The IGNITE study from Chinese researchers has demonstrated how plasma—and not just tissue samples—could be used to distinguish patients with non-small cell lung cancer who could benefit from EGFR-directed therapy and that significantly more...
GENEVA—An alternative way of testing for mutated EGFR in patients with advanced non-small cell lung cancer was validated in research presented at the European Lung Cancer Conference by Martin Reck MD PhD from the department of thoracic oncology at...
GENEVA— Almost one in four patients with advanced lung cancer in Europe, Asia and the US are not receiving EGFR test results before being started on treatment—according to a report presented at the European Lung Cancer Conference by James Spicer...
Growing Evidence that Anti BRAF Melanoma Drugs Benefit Some Patients with Non-Small Cell Lung Cancer
GENEVA—Findings from the retrospective EURAF study suggest that many patients with BRAF-mutant lung cancers could benefit from treatment with BRAF inhibitors, although specific studies need to be done to confirm this. Data presented at the European...
GENEVA—Two thirds of patients with advanced non-small cell lung cancer that had failed first line anti-EGFR therapy responded to a new drug: AZD9291 according to findings discussed at the European Lung Cancer Conference. Pasi Jänne MD PhD from the...
GENEVA—Reviews of CD8-positive T-cell infiltration as an independent prognostic biomarker in resected non-small cell lung cancer, and the potential of checkpoint inhibitor therapy for mesothelioma after first or second line chemotherapy were...
GENEVA—First or second-line chemotherapy with cisplatin-pemetrexed or gemcitabine does not preclude the use of checkpoint inhibitor therapy for mesothelioma later on—according to research presented at the European Lung Cancer Conference. Alessandra...